Thus, 7 days after stroke is an ideal time point to start treatment with bioengineered EVs loaded with VEGF, to capitalize on a period of peak integrin αVβ3 expression and endogenous neurogenesis without compromising safety. This evidence concerns the gene VEGFA and stroke disorder.